Tag Archives: Oyster Point Pharma Inc.

Biotech IPO scene shifts into pre-holiday slow gear, but several former IPOs are soaring with analysts saying Buy, Buy, Buy!

IPO Sector: US tech IPOs have mostly vanished in the fourth quarter following disappointments from multiple fast-growing, unprofitable unicorns. Healthcare (55% of 4Q IPOs) and Chinese issuers (24%) have hogged… Read more »

More Chinese medical companies choosing New York over Shanghai, Hong Kong for IPOs; but not always.

Three companies priced in New York last week–two biotechs and Chinese online real estate marketplace Shenzhen Fangdd Network Technology Co Ltd. (Nasdaq:DUO). The China-USA, free-floating trade anxieties aren’t dissuading the… Read more »

Health sector IPOs show no sign of cooling off as “rain dance” continues, and new money keeps showering hopefuls.

With signs that public support of Medicare for All is slipping, health-sector IPO action was on fire last week and, in general, there could be eight new IPOs priced this… Read more »